Business Context and Reporting Period
Pliant Therapeutics, Inc. (PLRX) filed a Form 8-K on March 11, 2026, to announce financial results for the fourth quarter ended December 31, 2025. The company is incorporated in Delaware and trades on The Nasdaq Stock Market LLC.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the press release furnished as Exhibit 99.1, which is referenced but not included in the provided text.
Material Changes
The filing does not detail specific material changes versus the prior comparable period. It serves solely as a notification that the fourth quarter 2025 results have been issued.
Guidance, Outlook, and Risks
The filing does not contain management commentary, guidance, outlook, or specific risk factors. It includes a standard disclaimer stating that the information in this Current Report and its exhibits shall not be deemed "filed" for purposes of Section 18 of the Exchange Act and shall not be incorporated by reference into other filings.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated March 11, 2026) for actual Q4 2025 financial figures.
- Verify the company's cash runway and burn rate in the full press release.
- Check for any updates on clinical trial progress or regulatory milestones mentioned in the press release.
- Confirm the status of the Series A Junior Participating Preferred Purchase Rights listed in the filing.